Why the study?
Does fondaparinux reduce venous thromboembolic events in hip fracture patients undergoing surgery?
Population
Hip fracture patients undergoing surgery
Comparison
Fondaparinux (1 week or extended to 4 weeks) vs Enoxaparin or placebo
Design
Review
Follow-up
up to 4 weeks
Authors
Loading...
May support fondaparinux prophylaxis after hip fracture surgery; leaves open need for contemporary RCTs to guide practice.
Does fondaparinux reduce venous thromboembolic events in hip fracture patients undergoing surgery?
Fondaparinux for up to 4 weeks significantly reduces the risk of venous thromboembolism after hip fracture surgery compared to enoxaparin or placebo.
Bengt I. Eriksson (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: